TOP TEN perturbations for 39667_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39667_at
Selected probe(set): 238904_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39667_at (238904_at) across 6674 perturbations tested by GENEVESTIGATOR:
HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Relative Expression (log2-ratio):1.849958Number of Samples:3 / 3
| Experimental | HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) |
| Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C. | |
| Control | HIF-1a/HIF-2a depletion study 1 (normoxia; AB81) |
| Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates. |
stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Relative Expression (log2-ratio):-1.5100985Number of Samples:3 / 4
| Experimental | stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. | |
| Control | stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. |
HIF-1a/HIF-2a depletion study 1 (normoxia; AB81) / control AB81 cell sample (normoxia)
Relative Expression (log2-ratio):-1.5042033Number of Samples:3 / 3
| Experimental | HIF-1a/HIF-2a depletion study 1 (normoxia; AB81) |
| Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates. | |
| Control | control AB81 cell sample (normoxia) |
| Human podocyte cell line AB81 treated with normoxia (20% O2) for 24 hours. Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates. |
HIF-2a depletion study 1 (normoxia; HK2) / HIF-1a depletion study 2 (normoxia; HK2)
Relative Expression (log2-ratio):-1.3763785Number of Samples:3 / 3
| Experimental | HIF-2a depletion study 1 (normoxia; HK2) |
| Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-2a (Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C. | |
| Control | HIF-1a depletion study 2 (normoxia; HK2) |
| Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a (Hypoxia-inducible factor 1-alpha) 24 hours after treatment with normoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C. |
stem cell differentiation study 41 (hES-T3 EB) / undifferentiated hES-T3 cell sample
Relative Expression (log2-ratio):-1.3662577Number of Samples:2 / 3
| Experimental | stem cell differentiation study 41 (hES-T3 EB) |
| Sample of embryonic bodies (EB) differentiated from human embryonic stem cells T3 with female karyotype. | |
| Control | undifferentiated hES-T3 cell sample |
| Undifferentiated human embryonic stem cells T3. |
small cell lung cancer study 4 (XCL from CDX) / small cell lung cancer study 4 (cell line)
Relative Expression (log2-ratio):-1.341815Number of Samples:11 / 4
| Experimental | small cell lung cancer study 4 (XCL from CDX) |
| Xenograft-derived cell lines (XCL) established from a small cell lung carcinoma (SCLC) publicly available cell lines derived xenografts (CDX derived cell lines). Xenografts were grown in the flanks of a nude mice. Obtained cells were cultivated under conventional tissue culture conditions. | |
| Control | small cell lung cancer study 4 (cell line) |
| Various small cell lung cancer (SCLC) publicly available cell lines samples. |
oligodendrocyte progenitor cell study 2 (O4-;CD140a+) / oligodendrocyte progenitor cell study 2 (O4-;CD140a-)
Relative Expression (log2-ratio):-1.2862196Number of Samples:5 / 5
| Experimental | oligodendrocyte progenitor cell study 2 (O4-;CD140a+) |
| Fetal oligodendrocyte cells between 20-22wk gestational age derived from fetal brains were FACS sorted on the basis of CD140a (PDGFRA) antigens. Samples were O4-/CD140a+. | |
| Control | oligodendrocyte progenitor cell study 2 (O4-;CD140a-) |
| Fetal oligodendrocyte cells between 20-22wk gestational age derived from fetal brains were FACS sorted on the basis of CD140a (PDGFRA) antigens. Samples were O4-/CD140a-. |
stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Relative Expression (log2-ratio):-1.2797203Number of Samples:3 / 4
| Experimental | stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. | |
| Control | stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. |
HIF-2a depletion study 1 (normoxia; HK2) / control HK2 cell sample (normoxia)
Relative Expression (log2-ratio):-1.2674832Number of Samples:3 / 6
| Experimental | HIF-2a depletion study 1 (normoxia; HK2) |
| Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-2a (Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C. | |
| Control | control HK2 cell sample (normoxia) |
| Proximal tubule epithelial cell line HK-2 treated with normoxia (20% O2) for 24 hours. HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C. |
atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):-0.9923849Number of Samples:5 / 6
| Experimental | atopic dermatitis study 21 (lesional; whole skin) |
| Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
| Control | normal skin tissue |
| Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |